Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Oncolys BioPharma submits IND application for new indication of OBP-301
Oncolys BioPharma Inc. <4588> announced after the close on June 3 that it has submitted an Investigational New Drug (IND) application to Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for a Phase 1b/2a clinical trial of its oncolytic virus OBP-301, targeting new indications of lower rectal and anal cancer. The study will evaluate the efficacy and safety of OBP-301 when combined with preoperative chemoradiotherapy. Oncolys plans to begin patient dosing within the fiscal year ending December 2026.
Source: MINKABU PRESS
*Translated by generative AI. Click here for the original article.
Related Articles
Bank of Japan exchange rate at 5 p.m.: dollar rises to 159.70-71 yen
Hong Kong's Hang Seng Index closes at 25,633.21 on the 3rd, down 405.11 points
Battery storage ranks 4th as METI announces revised battery and power industry strategy
Tokyo stocks close 1,667 yen higher, led by semiconductor-related shares to land in 68,000 yen range
Shanghai Composite Index closes at 4,083.9740 on the 3rd, up 8.8724 points
Seiwa HD to acquire plating business from Mitaka Metal Industries to strengthen production capacity amid semiconductor demand growth
Nikkei 225 close on the 3rd = rebound, 1,667 yen higher to 68,402 yen
PowerX prepares to apply for market section change to TSE Prime
WORLD CO., LTD. reports first year-on-year increase in existing store sales in three months for May
Active stocks on the 3rd (closing) - Rasa Industries, TerraSky, and ST and others